Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Graftless transcrestal sinus lift with self-tapping implants for the upper back jaw

Official title: Transcrestal Graftless Schneiderian Membrane Elevation by Self-tapping Dental Implant

Run by Sana'a University · NCT07424742 · Data updated 2026-11-12

This study will try a minimally invasive graftless transcrestal sinus lift with immediate implant placement for adults missing upper back teeth who have limited bone height.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment20 (estimated)
SponsorSana'a University
Academic / other
Locations1 site (Sanaa, Sanaa Governorate)
StatusRecruiting
StartedSeptember 9, 2024
Main results expectedAugust 8, 2026
Study endsSeptember 9, 2026
Registry record updatedJune 2, 2026
Trial IDNCT07424742 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 with an edentulous posterior maxilla, about 4–6 mm of remaining bone height, good general health (ASA I–II), and willingness to attend follow-up visits are ideal candidates.

Probably not a fit

Patients with severe systemic disease (ASA III+), uncontrolled diabetes, active sinus disease, prior head/neck radiotherapy, heavy smoking, pregnancy, untreated periodontal disease, or very low residual bone (<4 mm) are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective clinical study uses a transcrestal approach to gently lift (tent) the Schneiderian membrane and place self-tapping dental implants at the same time without adding graft material, relying on blood clot formation and natural bone regrowth beneath the membrane. Clinical and radiographic measurements will be taken before surgery, immediately after, and at six months to document new bone formation, implant stability, and osseointegration. The protocol tracks implant survival and complications over time to determine the safety and reliability of the technique in the posterior maxilla. The procedure is performed at a single center with standardized surgical and follow-up assessments.

Why it matters

Potential benefit: If successful, this approach could allow implants in the upper back jaw without bone grafts, reducing surgical complexity, costs, and recovery time.

How similar studies have gone: Previous clinical reports of graftless sinus elevation using membrane tenting and blood clot have shown promising bone formation and implant survival in selected patients, though results vary and longer-term data remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Adults aged 18-80 years.
2. Patients with edentulous posterior maxilla.
3. Residual bone height approximately 4-6 mm.
4. Indicated for transcrestal sinus membrane elevation.
5. Good general health (ASA I or II).
6. Ability to provide written informed consent.
7. Willingness to attend follow-up visits.

Exclusion Criteria:

1. Severe systemic diseases (ASA III or above).
2. Uncontrolled diabetes mellitus.
3. Active sinus pathology.
4. History of radiotherapy in the head and neck region.
5. Heavy smokers (\>10 cigarettes/day).
6. Pregnancy or lactation.
7. Untreated periodontal disease.

7\. Poor oral hygiene.

Where it's running

  • Department of Oral and Maxillofacial Surgery, Sana'a University
    Sanaa, Sanaa Governorate, Yemen
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.